{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:22:15Z","timestamp":1786980135355,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T00:00:00Z","timestamp":1571443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T00:00:00Z","timestamp":1571443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00415-019-09581-w","type":"journal-article","created":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T14:25:41Z","timestamp":1571495141000},"page":"267-275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Treatment of blepharospasm and Meige\u2019s syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice"],"prefix":"10.1007","volume":"267","author":[{"given":"Angela","family":"Jochim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Meindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Mantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Zwirner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Castrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5513-1839","authenticated-orcid":false,"given":"Bernhard","family":"Haslinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,19]]},"reference":[{"key":"9581_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fneur.2016.00045","volume":"7","author":"J Valls-Sole","year":"2016","unstructured":"Valls-Sole J, Defazio G (2016) Blepharospasm: update on epidemiology, clinical aspects, and pathophysiology. Front Neurol 7:45. \nhttps:\/\/doi.org\/10.3389\/fneur.2016.00045","journal-title":"Front Neurol"},{"issue":"4","key":"9581_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/mds.870090404","volume":"9","author":"M Aramideh","year":"1994","unstructured":"Aramideh M, Ongerboer de Visser BW, Koelman JH, Bour LJ, Devriese PP, Speelman JD (1994) Clinical and electromyographic features of levator palpebrae superioris muscle dysfunction in involuntary eyelid closure. Mov Disord 9(4):395\u2013402. \nhttps:\/\/doi.org\/10.1002\/mds.870090404","journal-title":"Mov Disord"},{"issue":"1","key":"9581_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.survophthal.2006.10.003","volume":"52","author":"JJ Dutton","year":"2007","unstructured":"Dutton JJ, Fowler AM (2007) Botulinum toxin in ophthalmology. Surv Ophthalmol 52(1):13\u201331. \nhttps:\/\/doi.org\/10.1016\/j.survophthal.2006.10.003","journal-title":"Surv Ophthalmol"},{"key":"9581_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-310266","author":"A Molloy","year":"2015","unstructured":"Molloy A, Williams L, Kimmich O, Butler JS, Beiser I, McGovern E, O'Riordan S, Reilly RB, Walsh C, Hutchinson M (2015) Sun exposure is an environmental factor for the development of blepharospasm. J Neurol Neurosurg Psychiatry. \nhttps:\/\/doi.org\/10.1136\/jnnp-2014-310266","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"9581_CR5","doi-asserted-by":"publisher","first-page":"e00894","DOI":"10.1002\/brb3.894","volume":"8","author":"A Jochim","year":"2018","unstructured":"Jochim A, Li Y, Gora-Stahlberg G, Mantel T, Berndt M, Castrop F, Dresel C, Haslinger B (2018) Altered functional connectivity in blepharospasm\/orofacial dystonia. Brain Behav 8(1):e00894. \nhttps:\/\/doi.org\/10.1002\/brb3.894","journal-title":"Brain Behav"},{"issue":"4","key":"9581_CR6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/mds.26934","volume":"32","author":"G Defazio","year":"2017","unstructured":"Defazio G, Hallett M, Jinnah HA, Conte A, Berardelli A (2017) Blepharospasm 40 years later. Mov Disord 32(4):498\u2013509. \nhttps:\/\/doi.org\/10.1002\/mds.26934","journal-title":"Mov Disord"},{"issue":"1","key":"9581_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/ene.13762","volume":"26","author":"A Albanese","year":"2019","unstructured":"Albanese A, Di Giovanni M, Lalli S (2019) Dystonia: diagnosis and management. Eur J Neurol 26(1):5\u201317. \nhttps:\/\/doi.org\/10.1111\/ene.13762","journal-title":"Eur J Neurol"},{"issue":"8","key":"9581_CR8","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00415-019-09349-2","volume":"266","author":"A Jochim","year":"2019","unstructured":"Jochim A, Meindl T, Mantel T, Zwirner S, Zech M, Castrop F, Haslinger B (2019) Treatment of cervical dystonia with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice. J Neurol 266(8):1879\u20131886. \nhttps:\/\/doi.org\/10.1007\/s00415-019-09349-2","journal-title":"J Neurol"},{"issue":"7","key":"9581_CR9","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","volume":"60","author":"J Jankovic","year":"2003","unstructured":"Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60(7):1186\u20131188","journal-title":"Neurology"},{"key":"9581_CR10","unstructured":"Allergan Pharmaceuticals Ireland I (2018) Fachinformation BOTOX\u00ae 50\/100\/200 Allergan-Einheiten; Approval number: 55006.00.00. \nhttps:\/\/www.fachinfo.de\/pdf\/020408\n\n. Accessed 19 June 2019"},{"key":"9581_CR11","unstructured":"Ipsen Pharma GmbH Ettlingen Germany G (March 2018) Fachinformation (Zusammenfassung der Merkmale des Arzneimittels) Dysport\u00ae 300 Einheiten\/500 Einheiten; Approval number: 50586.00.00. \nhttps:\/\/www.ipsen.com\/websites\/Ipsen_Online\/wp-content\/uploads\/sites\/21\/2018\/11\/14125820\/Fachinformation-Dysport-2018.pdf\n\n. Accessed 19 June 2019"},{"key":"9581_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.toxicon.2014.07.009","volume":"90","author":"J Ramirez-Castaneda","year":"2014","unstructured":"Ramirez-Castaneda J, Jankovic J (2014) Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon 90:344\u2013348. \nhttps:\/\/doi.org\/10.1016\/j.toxicon.2014.07.009","journal-title":"Toxicon"},{"issue":"1","key":"9581_CR13","doi-asserted-by":"publisher","first-page":"173 e172","DOI":"10.1016\/j.ajo.2013.02.001","volume":"156","author":"CN Czyz","year":"2013","unstructured":"Czyz CN, Burns JA, Petrie TP, Watkins JR, Cahill KV, Foster JA (2013) Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome. Am J Ophthalmol 156(1):173 e172\u2013177 e172. \nhttps:\/\/doi.org\/10.1016\/j.ajo.2013.02.001","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"9581_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00702-014-1278-z","volume":"122","author":"K Kollewe","year":"2015","unstructured":"Kollewe K, Mohammadi B, Kohler S, Pickenbrock H, Dengler R, Dressler D (2015) Blepharospasm: long-term treatment with either Botox(R), Xeomin(R) or Dysport(R). J Neural Transm (Vienna) 122(3):427\u2013431. \nhttps:\/\/doi.org\/10.1007\/s00702-014-1278-z","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"9581_CR15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/ceo.12165","volume":"42","author":"OH Ababneh","year":"2014","unstructured":"Ababneh OH, Cetinkaya A, Kulwin DR (2014) Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol 42(3):254\u2013261. \nhttps:\/\/doi.org\/10.1111\/ceo.12165","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"9581_CR16","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/eye.2009.192","volume":"24","author":"S Cillino","year":"2010","unstructured":"Cillino S, Raimondi G, Guepratte N, Damiani S, Cillino M, Di Pace F, Casuccio A (2010) Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes. Eye (Lond) 24(4):600\u2013607. \nhttps:\/\/doi.org\/10.1038\/eye.2009.192","journal-title":"Eye (Lond)"},{"issue":"4","key":"9581_CR17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13760-014-0285-z","volume":"114","author":"H Streitova","year":"2014","unstructured":"Streitova H, Bares M (2014) Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years. Acta Neurol Belg 114(4):285\u2013291. \nhttps:\/\/doi.org\/10.1007\/s13760-014-0285-z","journal-title":"Acta Neurol Belg"},{"issue":"4","key":"9581_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/112067210301300401","volume":"13","author":"P Calace","year":"2003","unstructured":"Calace P, Cortese G, Piscopo R, Della Volpe G, Gagliardi V, Magli A, De Berardinis T (2003) Treatment of blepharospasm with botulinum neurotoxin type A: long-term results. Eur J Ophthalmol 13(4):331\u2013336","journal-title":"Eur J Ophthalmol"},{"issue":"3","key":"9581_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.nrl.2012.03.009","volume":"28","author":"C Gil Polo","year":"2013","unstructured":"Gil Polo C, Rodriguez Sanz MF, Berrocal Izquierdo N, Castrillo Sanz A, Gutierrez Rios R, Zamora Garcia MI, Mendoza Rodriguez A, Duarte Garcia-Luis J (2013) Blepharospasm and hemifacial spasm: long-term treatment with botulinum toxin. Neurologia 28(3):131\u2013136. \nhttps:\/\/doi.org\/10.1016\/j.nrl.2012.03.009","journal-title":"Neurologia"},{"issue":"8","key":"9581_CR20","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1007\/s00115-008-2486-2","volume":"79","author":"T Vogt","year":"2008","unstructured":"Vogt T, Lussi F, Paul A, Urban P (2008) Long-term therapy of focal dystonia and facial hemispasm with botulinum toxin A. Nervenarzt 79(8):912\u2013917. \nhttps:\/\/doi.org\/10.1007\/s00115-008-2486-2","journal-title":"Nervenarzt"},{"issue":"5","key":"9581_CR21","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/mds.20376","volume":"20","author":"NI Mejia","year":"2005","unstructured":"Mejia NI, Vuong KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20(5):592\u2013597. \nhttps:\/\/doi.org\/10.1002\/mds.20376","journal-title":"Mov Disord"},{"issue":"6","key":"9581_CR22","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1002\/mds.10252","volume":"17","author":"GY Hsiung","year":"2002","unstructured":"Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O (2002) Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 17(6):1288\u20131293. \nhttps:\/\/doi.org\/10.1002\/mds.10252","journal-title":"Mov Disord"},{"issue":"5","key":"9581_CR23","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1017\/S0317167100010817","volume":"37","author":"HS Gill","year":"2010","unstructured":"Gill HS, Kraft SP (2010) Long-term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm. Can J Neurol Sci 37(5):631\u2013636","journal-title":"Can J Neurol Sci"},{"issue":"2A","key":"9581_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1590\/S0004-282X2005000200006","volume":"63","author":"L Silveira-Moriyama","year":"2005","unstructured":"Silveira-Moriyama L, Goncalves LR, Chien HF, Barbosa ER (2005) Botulinum toxin a in the treatment of blepharospasm: a 10-year experience. Arq Neuropsiquiatr 63(2A):221\u2013224","journal-title":"Arq Neuropsiquiatr"},{"issue":"3","key":"9581_CR25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s12640-009-9023-3","volume":"15","author":"AR Bentivoglio","year":"2009","unstructured":"Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A (2009) Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res 15(3):224\u2013231. \nhttps:\/\/doi.org\/10.1007\/s12640-009-9023-3","journal-title":"Neurotox Res"},{"issue":"5","key":"9581_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/01658107.2017.1409770","volume":"42","author":"M Wakakura","year":"2018","unstructured":"Wakakura M, Yamagami A, Iwasa M (2018) Blepharospasm in Japan: a clinical observational study from a large referral hospital in Tokyo. Neuroophthalmology 42(5):275\u2013283. \nhttps:\/\/doi.org\/10.1080\/01658107.2017.1409770","journal-title":"Neuroophthalmology"},{"issue":"2","key":"9581_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/1756285614557475","volume":"8","author":"A Hellman","year":"2015","unstructured":"Hellman A, Torres-Russotto D (2015) Botulinum toxin in the management of blepharospasm: current evidence and recent developments. Ther Adv Neurol Disord 8(2):82\u201391. \nhttps:\/\/doi.org\/10.1177\/1756285614557475","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"9581_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mds.22368","volume":"24","author":"J Jankovic","year":"2009","unstructured":"Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G (2009) Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord 24(3):407\u2013413. \nhttps:\/\/doi.org\/10.1002\/mds.22368","journal-title":"Mov Disord"},{"issue":"4","key":"9581_CR29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/mds.870100425","volume":"10","author":"V Lepore","year":"1995","unstructured":"Lepore V, Defazio G, Acquistapace D, Melpignano C, Pomes L, Lamberti P, Livrea P, Ferrari E (1995) Botulinum A toxin for the so-called apraxia of lid opening. Mov Disord 10(4):525\u2013526. \nhttps:\/\/doi.org\/10.1002\/mds.870100425","journal-title":"Mov Disord"},{"issue":"5","key":"9581_CR30","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0361-9230(97)00080-4","volume":"43","author":"G Defazio","year":"1997","unstructured":"Defazio G, Ribatti D, Nico B, Ricchiuti F, De Salvia R, Roncali L, Livrea P (1997) Endocytosis of horseradish peroxidase by brain microvascular and umbilical vein endothelial cells in culture: an ultrastructural and morphometric study. Brain Res Bull 43(5):467\u2013472","journal-title":"Brain Res Bull"},{"issue":"1","key":"9581_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3341\/kjo.2017.0030","volume":"32","author":"S Lee","year":"2018","unstructured":"Lee S, Park S, Lew H (2018) Long-term efficacy of botulinum neurotoxin-A treatment for essential blepharospasm. Korean J Ophthalmol 32(1):1\u20137. \nhttps:\/\/doi.org\/10.3341\/kjo.2017.0030","journal-title":"Korean J Ophthalmol"},{"issue":"9","key":"9581_CR32","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.ophtha.2006.03.055","volume":"113","author":"RL Levy","year":"2006","unstructured":"Levy RL, Berman D, Parikh M, Miller NR (2006) Supramaximal doses of botulinum toxin for refractory blepharospasm. Ophthalmology 113(9):1665\u20131668. \nhttps:\/\/doi.org\/10.1016\/j.ophtha.2006.03.055","journal-title":"Ophthalmology"},{"issue":"5","key":"9581_CR33","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1442-9071.2006.01236.x","volume":"34","author":"AL Pang","year":"2006","unstructured":"Pang AL, O'Day J (2006) Use of high-dose botulinum A toxin in benign essential blepharospasm: is too high too much? Clin Exp Ophthalmol 34(5):441\u2013444. \nhttps:\/\/doi.org\/10.1111\/j.1442-9071.2006.01236.x","journal-title":"Clin Exp Ophthalmol"},{"issue":"1","key":"9581_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0002-9394(03)00075-8","volume":"136","author":"M Snir","year":"2003","unstructured":"Snir M, Weinberger D, Bourla D, Kristal-Shalit O, Dotan G, Axer-Siegel R (2003) Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm. Am J Ophthalmol 136(1):99\u2013105","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"9581_CR35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s12640-012-9314-y","volume":"22","author":"C Colosimo","year":"2012","unstructured":"Colosimo C, Tiple D, Berardelli A (2012) Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res 22(4):265\u2013273. \nhttps:\/\/doi.org\/10.1007\/s12640-012-9314-y","journal-title":"Neurotox Res"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09581-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-019-09581-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09581-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T19:36:06Z","timestamp":1602963366000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-019-09581-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,19]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["9581"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09581-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,19]]},"assertion":[{"value":"13 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A. Jochim has received travel grants from Ipsen Pharma GmbH, Merz Pharmaceuticals GmbH, Pharm-Allergan GmbH, Boston Scientific, Bayer Health and Universit\u00e4tsklinikum W\u00fcrzburg as well as speaker honoraria from Pharm-Allergan GmbH. T. Meindl has received travel grants from Ipsen Pharma GmbH, Merz Pharmaceuticals GmbH, Pharm-Allergan GmbH and Boston Scientific Medizintechnik. GmbH. C. Huber has no conflicts of interest. T. Mantel has received travel grants from Bayer Vital GmbH. S. Zwirner has no conflicts of interest. F. Castrop has no conflicts of interest. B. Haslinger has received research support from the German Research Foundation (DFG), Pharm-Allergan GmbH and Ipsen Pharma GmbH, has received speaker honoraria from Pharm-Allergan GmbH and Bayer Health Care Pharmaceuticals and has received travel grants from Ipsen Pharma GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest:"}},{"value":"The study has been approved by the local ethics review board and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All patients whose data were not only acquired retrospectively, but also recorded prospectively, gave their written informed consent before entering the prospective phase of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}